On August 27, 2019 we posted “The Medicines Company Has Agreeable News” under Today’s Highlights.
The Medicines Company
We described The Medicines Company (MDCO) as a firm focused on cardiovascular diseases with a goal of halting the progression of atherosclerosis and lowering the cardiovascular risk caused by high levels of LDL Cholesterol (LDL-C). The Medicines Company’s good news emanated from the results of its first pivotal Phase 3 trial evaluating the safety, efficacy and tolerability of its inclisiran therapy designed to decrease LDL-C through twice yearly dosing. We witnessed the ORION-11 trial of inclisiran sodium 300 mg meeting all the primary and secondary endpoints with efficacy consistent with the findings from the Phase 1 and Phase 2 studies, and with safety almost equal to the placebo.
Yesterday, the full study results were presented during a late breaking science session at the European Society of Cardiology’s ESC Congress 2019 in Paris. For the primary endpoints of ORION-11 inclisiran delivered placebo-adjusted LDL-C reductions of 54% at day 510 and demonstrated time-averaged placebo-adjusted LDL-C reductions of 50% from days 90 through 540.